Abstract 2438
Background
This study was carried out as descriptive and cross-sectional in order to determine the compassion fatigue (CF), burnout (BO), compassion satisfaction (CS), perceived stress (PS) and psychological resilience (PR) levels of the nurses working in oncology-hematology and the factors affecting them.
Methods
The sample of the study consisted of 125 oncology-hematology nurses working in two private hospitals, one university hospital. The data were collected by personal information form, professional quality of life scale-IV, PS scale, and PR scale for adults. SPSS 24 package program was used to analyze the data of the study. Descriptive statistics, numbers and percentages and X±SD were used according to the data type. The factors affecting dependent variables were tested with multilevel models (MLM).
Results
In the study, 89.6% (n: 112) of the nurses were women, 80% (n: 100) were unmarried, 70.4% (n: 88) have Bachelor’s degree, mean age was 26.82±5.32, and the average years of total working at oncology was 2.78±2.35, the average weekly working hours was 49.75 ± 4.26, 65.6% (n: 82) said that the social support is not enough. When the mean scores of the nurses were examined, the CF was 13.53±7.25, BO was 20.14±6.77, CS was 37.92±7.40, PS was 32.00±3.44, PR was 135.43±17.29. There was a statistically significant effect of weekly working hour on BO, CS and PS (p < 0.05). 1 hour more work per week leads to a 0.5 point decrease in CS mean scores, 0,45 points increase in BO mean scores and 0,18 points increase in PS mean scores. When we compare the nurses their answers to social support question, nurses who said that social support is insufficient, have 3.1 points higher CF, 2.6 points lower CS, and 8.8 points lower PR mean scores (p < 0.05).
Conclusions
In this study, it was found that nurses had moderate levels of CF, BO and CS. While having social support positively affected the dependent variables, it was found that the increase in the weekly working hours negatively affected. These results are a key finding for the managers of the institutions especially in providing the healthy working life of nurses.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tuğba Pehlivan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract